$NKTR Headlines AstraZeneca's NDA for Naloxegol accepted

New Post Public Reply Private Reply Replies (0) Message Board

Feb 6, 2014 at 11:03 AM

$NKTR Headlines

AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy

Russell 2000 Rebalance May Bring Huge Buying in Key Stocks 8:29 a.m. Jan. 31, 2014 - 247WallSt.com
Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape 8:44 a.m. Jan. 24, 2014 - Zacks.com
Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock 8:27 a.m. Jan. 23, 2014 - TheStreet.com
SA PRO: Top Long And Short Ideas, Wednesday January 22 7:30 a.m. Jan. 23, 2014 - Seeking Alpha
Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share 9:50 p.m. Jan. 22, 2014 - benzinga.com
Cowen names its top biotech stocks with biggest upside to buy in 2014 6:45 p.m. Jan. 22, 2014 - Seeking Alpha
Interesting NKTR Put And Call Options For March 22nd 11:56 a.m. Jan. 22, 2014 - TheStreet.com
Nektar Momentum Continues To Grow 11:52 a.m. Jan. 22, 2014 - Seeking Alpha
Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside 8:54 a.m. Jan. 22, 2014 - 247WallSt.com
Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock 3:14 p.m. Jan. 21, 2014 - benzinga.com
Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More 1:29 p.m. Jan. 21, 2014 - Seeking Alpha
Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium 11:34 a.m. Jan. 18, 2014 - benzinga.com
Pipeline Progress at Nektar - Analyst Blog 5:20 p.m. Jan. 16, 2014 - Zacks.com
Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential 7:20 a.m. Jan. 16, 2014 - 247WallSt.com
Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript) 4:05 p.m. Jan. 14, 2014 - Seeking Alpha
Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape 9:21 a.m. Jan. 14, 2014 - Zacks.com
Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape 7:21 a.m. Jan. 14, 2014 - Zacks.com
Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 7:18 a.m. Jan. 14, 2014 - benzinga.com
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape 8:37 a.m. Jan. 13, 2014 - Zacks.com
Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire 8:33 a.m. Jan. 10, 2014 - 247WallSt.com

Nektar Therapeutics Prices Public Offering of Common Stock 9:59 p.m. Jan. 22, 2014 - PR Newswire - PRF
Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock 4:10 p.m. Jan. 21, 2014 - PR Newswire - PRF
Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium 12:00 p.m. Jan. 18, 2014 - PR Newswire - PRF
Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 7:33 a.m. Jan. 16, 2014 - PR Newswire - PRF
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 8:15 a.m. Jan. 14, 2014 - PR Newswire - PRF
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA 5:38 p.m. Jan. 8, 2014 - PR Newswire
Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch 8:00 a.m. Dec. 25, 2013 - PR Newswire
AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 8:23 a.m. Dec. 17, 2013 - PR Newswire
New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 4:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 8:00 a.m. Oct. 28, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Prospanica Summit 2026: Envisioning More Opportunities Ahead

The Road to Envisioning 'Más': A Dive into the Future Let's break down what's ahead with the 2026 Prospanica Summit—a collision of ambition and opportunity set to strike at Marina Del Rey. It's a Saturday—November 7th to be exact—when all this goes down, aiming to shake up the aspirations of Hispanic MBAs and business pros from coast to coast. Think MBAs,...

TruGolf's E6 Golf Platform Hits 15,000 Courses Milestone

E6's Expanding Universe of Courses TruGolf's E6 is swinging big with a library that's breaking records—more than 15,000 real-world golf courses now available on demand. It's a leap of 50% in under a year, an impressive stride for any tech-driven platform, golfing or otherwise. The magic behind this growth? On-demand generation, allowing the software's library to expand...

Xona's $250M Raise: GPS Transformation Sparks Debate

The Satellite Race Heats Up: Xona's Ambitious Leap Hold onto your hats, folks, because Xona's making headlines with a $250 million infusion. This ain't just pocket change—it's part of a rocket-fueled mission to upend the GPS landscape. Imagine a world where GPS is 100 times stronger. That's the pitch, and folks, it's got the market buzzing. Valuation Rocketing: Investor...

Side Bolsters Art Division with Roboto Acquisition

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

Flood Insurance: Crucial for Silver Spring Owners?

Flood Risk: A Reality Check for Homeowners Alright folks, let's dive into a topic that's been soaking up attention lately—flood insurance in Silver Spring, Maryland. Seems like everyone assumes they're safe from watery doom if they're standing outside those high-risk FEMA flood zones. But here's the kicker: Glenda Martinez, the big cheese at Xcella Insurance Group,...

Chemours Set to Release Q3 2026 Results This November

Mark Your Calendars for Chemours' Upcoming Earnings If you've got a hand in Chemours' pie, circle November 2 on your calendar. That's the day they pull back the curtain on their Q3 2026 financial results. It's an after-market reveal, and if you're hoping to catch the full picture, they've lined up a conference call at 8:00 a.m. EST the very next day, on November 3. Early...

Cocoa Market Set to Reach $216.42B by 2031

The Sweet Path of Growth Chocolate's got a new aroma wafting over the market, and it's nothing to sniff at. We're looking at a global chocolate bonanza rocketing towards USD 216.42 billion by the time we wrap up 2031. From 2026's USD 178.33 billion, that's quite a leap, tracking an annual growth rate of about 3.9%. If you've got a sweet tooth for numbers, you're not...

Voter Power Flexes with Early Voting Celebrations

Voter Engagement Hits a New High with Nationwide Parties Well, look at that—voter turnout's got its own party scene now, and it's making waves. As Vote Early Day approaches, the folks at When We All Vote are cranking up the volume on civic engagement with what's touted as the biggest Party at the Polls program yet. With almost 700 get-togethers riffing across the U.S.,...

Former OB/GYN Faces $9M Verdict After Negligence Trial

A Tragic Verdict Worth Millions In the heart-wrenching case of former OB/GYN Arthur Park, the verdict has fallen like a ton of bricks. A jury in Bakersfield, California, has determined that Park's negligent care led to fatalities, resulting in a mammoth $9.25 million payout to two grief-stricken families. It's a bitter pill to swallow for Arthur Park, but an expected...

Cognizant AI Nexus Aims to Tame Enterprise AI Chaos

AI Investments Without Returns: The Current Scenario Well, wouldn't you know it? Enterprises have sunk a fortune into AI, and they're wagging their fingers once more at the mounting bills with little to show for it. Play the investment game long enough, and it seems you'll find the numbers don't always rub together and make sparks. This familiar tune of over-budget...